AstraZeneca's Farxiga Approved by FDA for Heart Failure
May 06 2020 - 2:42AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that its heart-failure treatment
Farxiga has been approved in the U.S. by the Food and Drug
Administration.
The U.K. pharmaceutical giant said Farxiga has been approved to
reduce the risk of cardiovascular death and hospitalization for
heart failure in adults with heart failure with reduced ejection
fraction with and without type-2 diabetes.
The decision follows the priority review designation granted by
the FDA earlier in 2020 and the fast-track designation granted
September 2019.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
May 06, 2020 02:27 ET (06:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
